RXRG and melanoma: After single cell RNA sequencing of BRAF-mutated patient-derived xenografts which were subjected to combined drug inhibition, the authors identified one cell population with a major regulation of a NC stem cell gene signature driven by the activation of nuclear receptor RXRG. Moreover, pharmacological inhibition of RXRG could delay the drug resistance onset of melanoma cells (Rambow et al., 2018).